What hasn’t been studied: evidence gaps

Gaps by topic

Full ratings: evidence ratings.

Safety gaps

Human trials have lasted up to 48 weeks,^[1] and the main animal safety study 91 days.^[2] There is little data on use over years, which is how many people take shilajit. Medication interactions haven’t been studied at all; see long-term safety data and interactions.

Population gaps

• Pregnancy and breastfeedingNot studied; see pregnancy.
• Children and teenagersNot studied; see children.
• Older adultsFew data; see older adults.
• People with health conditionsMostly excluded; see conditions.
• WomenFewer trials than men, though one triple-blind trial studied women’s sexual function.^[3]

The preparation gap

Several of the best-known trials used the same branded, standardised extract.^[4][5][6][1] Almost nothing compares different preparations directly, such as resin versus extract, or products from different regions. That makes it hard to apply findings to the wide range of products sold; see why research often can’t be applied to every product.

The replication gap

Most positive findings come from single trials. Few have been repeated by independent groups with different preparations. Without replication, even a promising result remains uncertain; see why one study doesn’t prove a claim.

What reviews say

A 2019 review of shilajit research described its biochemical and therapeutic promise but highlighted the need for better clinical evidence,^[7] and a 2011 review raised concerns about the design of some early studies.^[8] The picture has improved since, but the gaps listed here remain.

A note on cancer research

Cancer findings come from cell and animal studies, and a 2026 systematic review found no human clinical evidence.^[9] One laboratory study found shilajit reduced the effect of two chemotherapy drugs on cancer cells,^[10] which is a reason for caution rather than hope; see cancer research.

Why the gaps exist

Natural products are hard to patent, so there is limited commercial incentive for large trials, and public funding for supplement research is scarce. Shilajit’s variability also makes it difficult to define what is being studied. These are reasons for the gaps, not evidence of benefit or harm.

What the gaps mean for you

Gaps mean unknowns, not proven harms or proven benefits. Treat claims in unstudied areas with scepticism, take extra care in groups without safety data, and choose well-tested products to manage the risks that are known; see is shilajit safe?

Studies that would help most

• Larger, longer trialsHundreds of participants over a year or more.
• Independent replicationDifferent groups and preparations.
• Head-to-head comparisonsResin versus extracts.
• Interaction studiesWith common medicines.
• Broader populationsOlder adults and people with conditions.

Putting it into practice

When you see a claim about shilajit, check its topic against the table above. If it falls in a preclinical-only or unstudied area, treat it as a hypothesis, not a fact. If it falls in a limited area, look at which preparation and population were studied before applying it to yourself.

Signs of progress

The evidence has grown over the past two decades, with randomised trials in several areas and a 48-week bone study in postmenopausal women.^[1] These are real steps forward. They also show how much more work is needed before shilajit’s effects can be described with confidence across different products and people.

In short

Knowing where the evidence stops is as useful as knowing where it starts. It tells you which claims to question and where caution matters most.

How we track new evidence

We monitor new shilajit studies and update our evidence ratings when significant research is published. New studies are recorded in our new studies log, and rating changes are noted in our updates log. If you know of a study we haven’t covered, please tell us. A single new trial may not change a rating on its own, but replication or larger studies could move topics up the scale. We will keep these gaps under review and update this page as the evidence develops. New research is welcome, and so are corrections from readers.

The bottom line

Shilajit research has real gaps: unstudied topics, preclinical-only areas, limited long-term safety data, missing populations, one dominant extract and little replication. Read any claim in light of these gaps, and expect our ratings to change as new studies appear.

Related reading